Daridorexant is a dual orexin receptor antagonist developed by Idorsia Pharmaceuticals for the treatment of insomnia. The compound is identified by U.S. Patent 9,790,208.
What is U.S. Patent 9,790,208 for?
U.S. Patent 9,790,208 covers the chemical compound daridorexant and its use in treating sleep disorders [1]. This patent is foundational for Idorsia Pharmaceuticals' development and commercialization of the drug.
When Does the Patent for Daridorexant Expire?
The expiration date for U.S. Patent 9,790,208 is March 26, 2028 [1]. However, other patents related to daridorexant's formulation, manufacturing, or methods of use may extend market exclusivity beyond this date. DrugPatentWatch.com tracks such patent landscapes for pharmaceutical products [1].
What is Daridorexant Used For?
Daridorexant, marketed as Quviviq, is prescribed to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It works by blocking the wakefulness-promoting actions of orexins in the brain [3].
How Does Daridorexant Work?
Daridorexant functions as a dual orexin receptor antagonist (DORA). Orexins are neuropeptides that play a crucial role in regulating arousal and wakefulness. By inhibiting the binding of orexins to their receptors (OX1R and OX2R), daridorexant reduces the drive for wakefulness, thereby facilitating sleep [3].
What are the Side Effects of Daridorexant?
Common side effects reported for daridorexant include somnolence, headache, and fatigue [2]. It is important for patients to discuss potential side effects with their healthcare provider.
Can Generic Versions of Daridorexant Be Available Before Patent Expiry?
The availability of generic versions of daridorexant is dependent on the expiry of all relevant patents, including U.S. Patent 9,790,208 and any other Orange Book-listed patents. Legal challenges or the expiration of other forms of market exclusivity, such as data exclusivity, can also influence the timeline for generic entry. Information on patent expirations and potential generic competition can be found on resources like DrugPatentWatch.com [1].
Who Manufactures Daridorexant?
Daridorexant is developed and manufactured by Idorsia Pharmaceuticals [2].
What is the Difference Between Daridorexant and Other Sleep Medications?
Daridorexant belongs to a class of medications called dual orexin receptor antagonists, which differ from traditional sleep aids like benzodiazepines or non-benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone) that act on GABA receptors to promote sedation [3]. Unlike older medications that directly induce sleep, daridorexant works by reducing the brain's wakefulness drive.
What Clinical Data Supports Daridorexant's Efficacy?
Clinical trials for daridorexant have demonstrated its efficacy in improving sleep onset and sleep maintenance in adults with insomnia. For example, studies have shown statistically significant improvements in objective and subjective measures of sleep [2].
What are the Risks Associated with Daridorexant?
Potential risks associated with daridorexant include daytime impairment and sleep paralysis. Due to its effects on wakefulness, patients are advised to avoid activities requiring full alertness, such as driving, if they experience somnolence after taking the medication. The drug also carries a risk of complex sleep behaviors [2].
Sources:
1. https://drugpatentwatch.com/
2. Idorsia Pharmaceuticals. Quviviq (daridorexant) Prescribing Information.
3. U.S. Patent 9,790,208.